This site is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here
_
Dr Paul Nathan presents the data on the use of Tafinlar (dabrafenib) + Mekinist (trametinib) in the adjuvant setting for management of adult patients with BRAF V600 stage III melanoma, following complete resection. Filmed August 2018.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]
